FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

July 31 2018 A class 3 recall for sodium cromoglicate 2% w/v eye drops and Murine Hayfever Relief...

Effect of omega-3 on heart disease is negligible, finds Cochrane review

Effect of omega-3 on heart disease is negligible, finds Cochrane review

July 19 2018 Cochrane researchers have published research indicating that omega 3 supplements...

BLF highlights decline in stop smoking prescriptions

BLF highlights decline in stop smoking prescriptions

July 18 2018 There has been a 75% decline in stop smoking treatments being prescribed by GPs and...

Welsh National Survey includes OTC medicine purchases for first time

Welsh National Survey includes OTC medicine purchases for first time

June 28 2018 Over half the population in Wales has reported having bought an over the counter...

Recall issued for several own label glycerine and blackcurrant cough syrups

Recall issued for several own label glycerine and blackcurrant cough syrups

June 20 2018 A Class 2 Drug Recall has been issued for 15 batches of own-brand children’s...

  • FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

    FDC Int recalls a batch of sodium cromoglicate eye drops and of Murine Hayfever Relief

    Tuesday, 31 July 2018 15:24
  • Effect of omega-3 on heart disease is negligible, finds Cochrane review

    Effect of omega-3 on heart disease is negligible, finds Cochrane review

    Thursday, 19 July 2018 10:21
  • BLF highlights decline in stop smoking prescriptions

    BLF highlights decline in stop smoking prescriptions

    Wednesday, 18 July 2018 17:32
  • Welsh National Survey includes OTC medicine purchases for first time

    Welsh National Survey includes OTC medicine purchases for first time

    Thursday, 28 June 2018 16:55
  • Recall issued for several own label glycerine and blackcurrant cough syrups

    Recall issued for several own label glycerine and blackcurrant cough syrups

    Wednesday, 20 June 2018 18:29

Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

a pharmacist woman consultSeptember 4 2017

Boots has announced it is starting to make available a cheaper generic levonorgestrel product for its emergency hormonal contraception service. It means it can offer the EHC service at a cost of £15.99.

 The announcement follows criticism some months ago about the price it charged, when competitors were reducing prices by not using branded medicines. Boots has now issued a statement saying: “We have listened to our customers’ feedback and we committed to sourcing a less expensive EHC medicine to enable us to make a privately funded EHC service more accessible in the future.

“We can confirm that four weeks ago we started the roll out of this service to 38 stores and have been offering it with a new, less expensive generic version of EHC (levonorgestrel) at a cost of £15.99; which reflects the cost of the medicine and the regulated mandatory consultation with the pharmacist.”

The company added that it has been working with the manufacturer to increase supply with the intention of being able to offer the generic medicine across all stores from October. “We wanted to be assured of supply and a roll out date before confirming this publicly,” it said.

“Boots will offer the generic version of levonorgestrel alongside Ella One, Levonelle and Boots Pharmaceuticals (Levonelle) options to ensure we can provide a range of solutions that are right depending on a woman’s individual circumstances and according to the guidance from the Faculty of Sexual and Reproductive Healthcare.”

Link:
Boots statement               

OTC News

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...